Headquartered in Burlington, MA Fiscal year ends December NYSE: BFLY butterflynetwork.com
Butterfly Network, Inc. (NYSE: BFLY) is a medical device and semiconductor technology company that developed proprietary Ultrasound-on-Chip™ technology to drive a digital revolution in ultrasound imaging and sensing. The company commercialized the world's first single-probe, whole-body portable ultrasound device, now in its third generation (Butterfly iQ3™), combining advanced hardware with cloud software, AI, and an enterprise workflow solution called Compass AI™. Butterfly enables third-party development of imaging AI applications through Butterfly Garden™, its software development kit and AI marketplace. Beyond its core point-of-care ultrasound (POCUS) medical imaging business, the company operates Butterfly Embedded™, an Ultrasound-on-Chip licensing and co-development business that enables partners to build novel ultrasound applications across healthcare and non-healthcare markets using Butterfly's proprietary semiconductor chip and software platform. The company currently has 11 Embedded partners. Butterfly is also developing a Home & Community Care business expected to begin commercial implementation in the second half of 2026. The company sells to health systems, medical schools, government agencies, and direct-to-consumer via eCommerce, with operations in the United States and international markets including a recent expansion into Brazil. Updated
December has brought big insider purchases in shares of GE Aerospace and others. That was not the only notable insider buying seen, though.
Is it too late for investors to jump on the artificial intelligence bandwagon? There may still be opportunities, like this medical diagnostics company.
Butterfly Network, Inc. (NYSE: BFLY) is a medical device and semiconductor technology company that developed proprietary Ultrasound-on-Chip™ technology to drive a digital revolution in ultrasound imaging and sensing.
The Wall Street consensus 12-month price target for BFLY is $11.40.
